Palak J Trivedi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4315588/publications.pdf

Version: 2024-02-01

57 papers	3,520 citations	147801 31 h-index	155660 55 g-index
60 all docs	60 docs citations	60 times ranked	3428 citing authors

#	Article	IF	Citations
1	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
2	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	1.3	355
3	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	1.3	330
4	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	3.7	202
5	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	12.1	139
6	The gut-adherent microbiota of PSCâ€“IBD is distinct to that of IBD. Gut, 2017, 66, 386.1-388.	12.1	132
7	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of Hepatology, 2014, 60, 1249-1258.	3.7	113
8	Mucosal immunity in liver autoimmunity: A comprehensive review. Journal of Autoimmunity, 2013, 46, 97-111.	6.5	110
9	Review article: overlap syndromes and autoimmune liver disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 517-533.	3.7	109
10	Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. Journal of Crohn's and Colitis, 2018, 12, S641-S652.	1.3	105
11	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology, 2020, 159, 915-928.	1.3	94
12	Gutâ€“liver immunity. Journal of Hepatology, 2016, 64, 1187-1189.	3.7	93
13	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut, 2021, 70, 1989-2003.	12.1	91
14	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	1.3	82
15	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology, 2017, 65, 907-919.	7.3	79
16	Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. Journal of Autoimmunity, 2016, 68, 98-104.	6.5	70
17	Systematic review with metaâ€analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 636-643.	3.7	64
18	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology, 2019, 69, 2120-2135.	7.3	58

#	Article	IF	Citations
19	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology, 2016, 63, 644-659.	7.3	57
20	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	4.4	57
21	Good Maternal and Fetal Outcomes for Pregnant Women WithÂPrimary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1179-1185.e1.	4.4	56
22	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
23	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	4.4	54
24	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut, 2018, 67, 1135-1145.	12.1	52
25	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Review of Clinical Pharmacology, 2016, 9, 13-26.	3.1	51
26	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. The Lancet Gastroenterology and Hepatology, 2021, 6, 156-158.	8.1	49
27	PSC, AIH and overlap syndrome in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 420-436.	1.5	47
28	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	3.7	47
29	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2785-2792.e3.	4.4	43
30	Treatment of autoimmune liver disease: current and future therapeutic options. Therapeutic Advances in Chronic Disease, 2013, 4, 119-141.	2.5	40
31	Grand round: Autoimmune hepatitis. Journal of Hepatology, 2019, 70, 773-784.	3.7	33
32	Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 957-965.	3.7	31
33	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1687-1700.e4.	4.4	31
34	The impact of ileal pouchâ€anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2018, 48, 322-332.	3.7	30
35	The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). Gastrointestinal Endoscopy, 2018, 88, 95-106.e2.	1.0	27
36	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	4.4	25

#	Article	IF	Citations
37	The Immunogenetics of Autoimmune Cholestasis. Clinics in Liver Disease, 2016, 20, 15-31.	2.1	22
38	Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. American Journal of Human Genetics, 2022, 109, 928-943.	6.2	22
39	Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments. Hepatology International, 2013, 7, 28-47.	4.2	15
40	Reply to: â€œAST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosisâ€• Journal of Hepatology, 2014, 61, 1445-1446.	3.7	12
41	Renaming primary biliary cirrhosisâ€”clarity or confusion?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 678-679.	17.8	11
42	Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 71-83.	2.4	10
43	Risk stratification in primary sclerosing cholangitis: Itâ€™s time to move on from replicating imperfection and break the glass ceiling. Journal of Hepatology, 2019, 71, 867-870.	3.7	9
44	FRI-062-Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patientsâ€™ perspective. Journal of Hepatology, 2019, 70, e412-e413.	3.7	6
45	Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial. BMJ Open Gastroenterology, 2021, 8, e000579.	2.7	6
46	Emerging drugs for the treatment of primary sclerosing cholangitis. Current Opinion in Pharmacology, 2022, 62, 23-35.	3.5	5
47	Mucosal immunity in primary sclerosing cholangitis: from the bowel to bile ducts and back again. Current Opinion in Gastroenterology, 2022, 38, 104-113.	2.3	5
48	Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. American Journal of Gastroenterology, 2018, 113, 1437-1439.	0.4	4
49	Challenges in the use of corticosteroids in the management of autoimmune hepatitis. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, 594-599.	0.5	4
50	Novel Use of Normothermic Machine Perfusion of the Liver: A Strategy to Mitigate Unexpected Clinical Events. Transplantation, 2020, 104, e281-e282.	1.0	4
51	Letter: the therapeutic potential of targeting <scp>CCL</scp>25/<scp>CCR</scp>9 in colonic inflammatory bowel disease â€“ reading between the lines. Alimentary Pharmacology and Therapeutics, 2016, 44, 307-308.	3.7	2
52	PS-016-Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data. Journal of Hepatology, 2019, 70, e12-e13.	3.7	2
53	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
54	FRI-061-Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis. Journal of Hepatology, 2019, 70, e412.	3.7	1

#	Article	IF	Citations
55	Editorial: liver disease in secondary careâ€”â€˜money or your lifeâ€™. Alimentary Pharmacology and Therapeutics, 2021, 54, 854-855.	3.7	1
56	M2049 Fracture Risk Assessment Using DXA and FRAX in Patients with Celiac Disease. Gastroenterology, 2009, 136, A-474.	1.3	0
57	Challenges in the use of corticosteroids in the management of autoimmune hepatitis. Gastrointestinal Nursing, 2019, 17, S30-S36.	0.1	0